These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Spindle cell cancer of bladder during cyclophosphamide therapy for Wegener's granulomatosis. Chasko SB; Keuhnelian JG; Gutowski WT; Gray GF Am J Surg Pathol; 1980 Apr; 4(2):191-6. PubMed ID: 7377464 [TBL] [Abstract][Full Text] [Related]
3. Squamous cell carcinoma of the bladder associated with cyclophosphamide therapy for Wegener's granulomatosis: a report of 2 cases. Stein JP; Skinner EC; Boyd SD; Skinner DG J Urol; 1993 Mar; 149(3):588-9. PubMed ID: 8437272 [TBL] [Abstract][Full Text] [Related]
4. The evolving paradigm of cancer risk related to cyclophosphamide therapy in granulomatosis with polyangiitis. Calatroni M; Buzio C; Vaglio A Rheumatology (Oxford); 2015 Aug; 54(8):1339-41. PubMed ID: 26018438 [No Abstract] [Full Text] [Related]
5. What is proper treatment for Wegener granulomatosis? Inoue K; Yoshikawa T; Kawahito Y; Sano H Arch Intern Med; 2001 Jul; 161(14):1777-8. PubMed ID: 11485512 [No Abstract] [Full Text] [Related]
6. Cyclophosphamide-induced cystitis and bladder cancer in patients with Wegener granulomatosis. Talar-Williams C; Hijazi YM; Walther MM; Linehan WM; Hallahan CW; Lubensky I; Kerr GS; Hoffman GS; Fauci AS; Sneller MC Ann Intern Med; 1996 Mar; 124(5):477-84. PubMed ID: 8602705 [TBL] [Abstract][Full Text] [Related]
7. [Cyclophosphamide-induced bladder cancer in a patient with Wegener granuromatosis]. Shimizu A; Ueda T; Furuya Y; Ichikawa T; Akakura K; Ito H; Matsuzaki O; Isaka S Nihon Hinyokika Gakkai Zasshi; 1999 Jan; 90(1):53-6. PubMed ID: 10067308 [TBL] [Abstract][Full Text] [Related]
8. Carcinosarcoma of the urinary bladder following cyclophosphamide therapy: evidence for monoclonal origin and chromosome 9p allelic loss. Mukhopadhyay S; Shrimpton AE; Jones LA; Nsouli IS; Abraham NZ Arch Pathol Lab Med; 2004 Jan; 128(1):e8-11. PubMed ID: 14692829 [TBL] [Abstract][Full Text] [Related]
9. Prolonged risk of specific malignancies following cyclophosphamide therapy among patients with granulomatosis with polyangiitis. Faurschou M; Mellemkjaer L; Voss A; Keller KK; Hansen IT; Baslund B Rheumatology (Oxford); 2015 Aug; 54(8):1345-50. PubMed ID: 25234661 [TBL] [Abstract][Full Text] [Related]
10. Cyclophosphamide-induced hepatitis in Wegener's granulomatosis. Du LT; Rigaud D; Papo T; Godeau P Mayo Clin Proc; 1994 Sep; 69(9):912-3. PubMed ID: 8065199 [No Abstract] [Full Text] [Related]
11. Cyclophosphamide-induced hepatotoxicity in a patient with Wegener's granulomatosis. Snyder LS; Heigh RI; Anderson ML Mayo Clin Proc; 1993 Dec; 68(12):1203-4. PubMed ID: 8246624 [TBL] [Abstract][Full Text] [Related]
12. Does hepatocellular carcinoma develop after treatment of Wegener's granulomatosis with cyclophosphamide? Ueno T; Sata M Intern Med; 2003 May; 42(5):379-80. PubMed ID: 12793704 [No Abstract] [Full Text] [Related]
13. Urinary bladder cancer in Wegener's granulomatosis: risks and relation to cyclophosphamide. Knight A; Askling J; Granath F; Sparen P; Ekbom A Ann Rheum Dis; 2004 Oct; 63(10):1307-11. PubMed ID: 15130900 [TBL] [Abstract][Full Text] [Related]
14. Cyclophosphamide-associated leukemia in Wegener's granulomatosis. Wheeler GE Ann Intern Med; 1981 Mar; 94(3):361-2. PubMed ID: 7224386 [No Abstract] [Full Text] [Related]